Investigate / DXCM
Understand DEXCOM INC
Can Dexcom keep expanding CGM use while Medicare competitive bidding and payor pricing pressure reshape what it is paid per system?
Snapshot reviewed 2026-10-02. Source published 2026-07-30. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Ownership-page coverage is not available for this company. That does not mean no tracked investor owns it.
Your research workspace / DXCM
Ask better questions. Keep the evidence.
Explore the available sources for DEXCOM INC, then keep what deserves another look.
01 Investor activity
Ownership coverage is unavailable—not zero owners.
02 Business evidence
Reported evidence
What does the company do?
Dexcom designs, develops and commercializes continuous glucose monitoring systems used by patients, caregivers and clinicians to manage diabetes and metabolic health.
Latticework interpretation
What could support the case?
If the over-the-counter Stelo biosensor reaches adults with prediabetes and non-insulin-treated diabetes, Dexcom could expand beyond its traditional prescription channels.
Latticework interpretation
What could break the case?
If competitive bidding lowers Medicare reimbursement for CGM systems as expected, Dexcom’s pricing could come under pressure.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
Dexcom designs, develops and commercializes continuous glucose monitoring systems used by patients, caregivers and clinicians to manage diabetes and metabolic health.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-30. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue from customer contracts ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. Excludes assessed tax; this concept may exclude other company revenue. | $1,308.4m | $1,157.1m |
| Operating income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $318.3m | $212.6m |
| Net income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $249.1m | $179.8m |
| Operating cash flow ↗Six months (year to date): 2026-01-01–2026-06-30; prior 2025-01-01–2025-06-30Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $794.8m | $486.8m |
3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If the over-the-counter Stelo biosensor reaches adults with prediabetes and non-insulin-treated diabetes, Dexcom could expand beyond its traditional prescription channels.
Supporting filing ↗The strongest caution
If competitive bidding lowers Medicare reimbursement for CGM systems as expected, Dexcom’s pricing could come under pressure.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
How exposed is revenue to Medicare reimbursement?
Starting evidence: CMS extended competitive bidding to Dexcom’s CGMs and receivers, with contracting and payment changes scheduled for later periods.
Investigate next: Review the revenue split by payer and region, and what share depends on Medicare reimbursement.
Read the supporting filing ↗Can lower prices be offset by lower unit costs?
Starting evidence: Dexcom has experienced and expects further price decreases related to Medicare reimbursement changes and managed-care payor pressure.
Investigate next: Compare gross margin and per-unit cost trends against reported price changes in recent quarterly filings.
Read the supporting filing ↗Is the consumer and new-population push gaining traction?
Starting evidence: Dexcom is exploring offerings for prediabetes, obesity, pregnancy and hospital settings, and potentially products beyond glucose monitoring.
Investigate next: Look for Stelo adoption disclosures, partnership agreements and spending on these initiatives in upcoming reports.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.